Jozefa Wesierska-Gadek

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi request reprint Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Division Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, Vienna, Austria
    Acta Biochim Pol 56:495-501. 2009
  2. pmc PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Dept of Medicine I, Div Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    Biochem Pharmacol 84:1318-31. 2012
  3. doi request reprint The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Division Institute of Cancer Research, Dept of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    Future Med Chem 4:395-424. 2012
  4. pmc Tubulohelical membrane arrays: From the initial observation to the elucidation of nanophysical properties and cellular function
    Siegfried Reipert
    Department of Biochemistry and Cell Biology, Max F, Perutz Laboratories, University of Vienna, Dr, Bohrgasse 9, A 1030 Vienna, Austria
    PMC Biophys 3:13. 2010
  5. doi request reprint Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Div Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    Biochem Pharmacol 76:1503-14. 2008
  6. ncbi request reprint A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L-744,832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 104:189-201. 2008
  7. ncbi request reprint A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 102:1405-19. 2007
  8. doi request reprint Whether to target single or multiple CDKs for therapy? That is the question
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Div, Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    J Cell Physiol 226:341-9. 2011
  9. ncbi request reprint Characterization of the antibodies to p62 nucleoporin in primary biliary cirrhosis using human recombinant antigen
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 104:27-37. 2008
  10. ncbi request reprint Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Division Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8 a, A 1090 Vienna, Austria
    Food Chem Toxicol 46:1327-33. 2008

Collaborators

Detail Information

Publications65

  1. ncbi request reprint Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Division Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, Vienna, Austria
    Acta Biochim Pol 56:495-501. 2009
    ..This protein after de novo synthesis and translocation into the mitochondria promotes depolarization of the mitochondrial membrane...
  2. pmc PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Dept of Medicine I, Div Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    Biochem Pharmacol 84:1318-31. 2012
    ....
  3. doi request reprint The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Division Institute of Cancer Research, Dept of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    Future Med Chem 4:395-424. 2012
    ..The pharmacological CDK inhibitors have great potential for use in combination with other therapeutics and represent promising tools for the development of new curative treatments for CLL...
  4. pmc Tubulohelical membrane arrays: From the initial observation to the elucidation of nanophysical properties and cellular function
    Siegfried Reipert
    Department of Biochemistry and Cell Biology, Max F, Perutz Laboratories, University of Vienna, Dr, Bohrgasse 9, A 1030 Vienna, Austria
    PMC Biophys 3:13. 2010
    ..Finally, we raise the question of whether putative nanooptical properties of TUHMAs could serve for communicating orientation between dividing cells.MCS codes: 92C37, 92C05, 92C50...
  5. doi request reprint Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Div Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    Biochem Pharmacol 76:1503-14. 2008
    ..The increase of p53 protein coincides with down-regulation of E6 oncoprotein. Thus, the biological action of substituted purines is not restricted to the inhibition of CDKs and open new perspectives for their therapeutic applications...
  6. ncbi request reprint A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L-744,832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 104:189-201. 2008
    ..Importantly, best therapeutic effects can be achieved by post-treatment with inhibitors of FPTase...
  7. ncbi request reprint A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 102:1405-19. 2007
    ..These results were subsequently confirmed by immunoblotting. Further experiments revealed that OLO, but not ROSC, strongly up-regulates CLIMP-63 in a dose- and time-dependent manner solely in senescent cells...
  8. doi request reprint Whether to target single or multiple CDKs for therapy? That is the question
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Div, Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    J Cell Physiol 226:341-9. 2011
    ..This review offers a critical assessment of the advantages and disadvantages of both pan-specific and highly selective CDK inhibitors in therapy...
  9. ncbi request reprint Characterization of the antibodies to p62 nucleoporin in primary biliary cirrhosis using human recombinant antigen
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 104:27-37. 2008
    ....
  10. ncbi request reprint Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Division Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8 a, A 1090 Vienna, Austria
    Food Chem Toxicol 46:1327-33. 2008
    ..These results indicate that targeted combination of anti-cancer drugs with distinct naturally occurring compounds could increase the efficacy of the therapy and concomitantly reduce the undesired side effects exerted by cytostatic drugs...
  11. ncbi request reprint Signaling of DNA damage is not sufficient to induce p53 response: (re)activation of wt p53 protein strongly depends on cellular context
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Division Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8 a, A 1090 Vienna, Austria
    J Cell Biochem 103:1607-20. 2008
    ..This implicates that the capability of different agents to activate p53 in HeLaS(3) cells primarily depends on their inhibitory effect on expression of E6 oncoprotein...
  12. ncbi request reprint Characterization of autoantibodies against components of the nuclear pore complexes: high frequency of anti-p62 nucleoporin antibodies
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Div Institute of Cancer Research, Department of Medicine I, Vienna Medical University, Austria
    Ann N Y Acad Sci 1109:519-30. 2007
    ..Considering the recently reported clinical significance of ANAs in PBC, the prognostic value of the anti-NPC antibodies and their correlation with severity and progression of the disease is under evaluation...
  13. ncbi request reprint Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest
    Jozefa Wesierska-Gadek
    Department of Medicine I, Div Institute of Cancer Research, Vienna Medical University, Vienna, Austria
    J Cell Biochem 102:736-47. 2007
    ..Evidently, the combined treatment sensitizes MCF-7 cells to the action of ROSC, thereby allowing to reduce the dose of the drug and to minimize side effects...
  14. doi request reprint Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Div Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 105:1161-71. 2008
    ..These results indicate that therapy of HeLaS(3) cells by ROSC could offer an advantage over that by CP due to its increased selectivity and markedly reduced risk of generation of a secondary cancer...
  15. doi request reprint Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Div Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 106:937-55. 2009
    ..These results show that inhibition of CDKs by ROSC in cells lacking the G(1)/S restriction checkpoint has different outcomes depending on the cell-cycle status prior to the onset of treatment...
  16. doi request reprint Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria
    Future Med Chem 4:51-72. 2012
    ..This review focuses on the outcomes of the combined action of PARP-1 inhibitors and agents that affect the activity of DNA topoisomerases...
  17. doi request reprint The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications
    Jozefa Wesierska-Gadek
    Medical University of Vienna, Department of Medicine I, Institute of Cancer Research, Comprehensive Cancer Center, Cell Cycle Regulation Group, Borschkegasse 8a, 1090 Vienna, Austria
    Expert Opin Investig Drugs 20:1611-28. 2011
    ..For these reasons, cell cycle regulators are regarded as very promising therapeutic targets for the treatment of human malignancies...
  18. doi request reprint Novel potent pharmacological cyclin-dependent kinase inhibitors
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, A 1090 Vienna, Austria
    Future Med Chem 1:1561-81. 2009
    ..Recent discoveries in cell cycle regulation have provided rationales for clinical applications of CDK inhibitors in both monotherapeutic and combined therapeutic regimens...
  19. ncbi request reprint Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine Div Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Austria
    Curr Pharm Des 17:256-71. 2011
    ....
  20. doi request reprint Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 112:761-72. 2011
    ..Furthermore, our data show that ROSC can be combined with anti-estrogen therapy. The inhibitory effect of TAM on ER-negative cancer cells indicates that SERMs crosstalk with other steroid hormone receptors...
  21. doi request reprint Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors
    Jozefa Wesierska-Gadek
    Dept of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 112:273-88. 2011
    ..These results indicate that reconstitution of MCF-7 cancer cells with caspase-3 sensitize them to the action of DNA damaging agents but not to ATP-like pharmacological inhibitors of CDKs...
  22. doi request reprint Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Division Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    Ann N Y Acad Sci 1171:228-41. 2009
    ..In this article the action and specificity of CDK inhibitor roscovitine, belonging to the group of purine analogues, is reviewed and the rationale for dissecting the inhibitory action on cell cycle and transcriptional CDKs is discussed...
  23. ncbi request reprint Effect of distinct anticancer drugs on the phosphorylation of p53 protein at serine 46 in human MCF-7 breast cancer cells
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Division Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8 a, A 1090 Vienna, Austria
    Ann N Y Acad Sci 1095:45-52. 2007
    ..These results indicate that p53 activation is dispensable for DOX-induced G2 arrest. Moreover, the pattern of p53 phosphorylation strongly depends on the type of the stimulating factor...
  24. ncbi request reprint Role of p53 tumor suppressor in ageing: regulation of transient cell cycle arrest and terminal senescence
    J Wesierska-Gadek
    Cell Cycle Regulation Group, Institute of Cancer Research, Vienna Medical University, Vienna, Austria
    J Physiol Pharmacol 56:15-28. 2005
    ..Analysis of the expression of distinct cell cycle regulators revealed that quiescent MRC-5 cells were in G0 phase. Our results indicate that cell cycle arrest occurring in senescent cells is associated with the G0 transition...
  25. ncbi request reprint In vivo activated caspase-3 cleaves PARP-1 in rat liver after administration of the hepatocarcinogen N-nitrosomorpholine (NNM) generating the 85 kDa fragment
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Institute of Cancer Research, Vienna, Austria
    J Cell Biochem 93:774-87. 2004
    ..It remains to elucidate which additional factors may be involved in the modulation of cellular response to the strong insults thereby activating different pathways and generating distinct outcomes...
  26. ncbi request reprint Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    Cancer Res 64:4487-97. 2004
    ..Our data also suggest that the PARP-1 status might be essential for the maintenance of the G(2) arrest induced by C-1305...
  27. doi request reprint Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Institute of Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 112:1103-17. 2011
    ..Our results demonstrate that ROSC negatively affects the functional status of ER-α, making it potentially useful in the treatment of estrogen-dependent breast cancer cells...
  28. ncbi request reprint Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action
    Jozefa Wesierska-Gadek
    Department of Medicine I, Cell Cycle Regulation Group, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 95:1012-28. 2005
    ..Simultaneous inhibition of P-gp in cells lacking PARP-1 resulted in an accumulation of cells in G2. Exposure of mouse cells to high DOX dose activated significantly caspase-3/7 in PARP-1 KO cells...
  29. ncbi request reprint A new multiplex assay allowing simultaneous detection of the inhibition of cell proliferation and induction of cell death
    Jozefa Wesierska-Gadek
    Department of Medicine I, Cell Cycle Regulation Group, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 96:1-7. 2005
    ..The new multiplexing assay offers a range of benefits over standard assays...
  30. ncbi request reprint Physiological ageing: role of p53 and PARP-1 tumor suppressors in the regulation of terminal senescence
    J Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Institute of Cancer Research, Vienna Medical University, Vienna, Austria
    J Physiol Pharmacol 56:77-88. 2005
    ..Moreover, the interaction and cross-talk between p53 and PARP1-1 was discussed...
  31. ncbi request reprint Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8 a, A 1090 Vienna, Austria
    Mol Cancer Ther 4:113-24. 2005
    ..Remarkably, roscovitine failed to induce phosphorylation at Ser46 in caspase-3-reconstituted MCF-7 cells. Our results indicate that, depending on the status of caspase-3 in MCF-7 cells, different apoptotic pathways were initialized...
  32. ncbi request reprint The subcellular distribution of the p53 tumour suppressor, and organismal ageing
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Div Institute of Cancer Research, Dept of Medicine I, Vienna Medical University, Borschkegasse 8 a, A 1090 Vienna, Austria
    Cell Mol Biol Lett 10:439-53. 2005
    ..This paper presents an overview of the role of p53 in cellular senescence and the regulation of p53 activity by its intracellular distribution...
  33. ncbi request reprint Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein
    Jozefa Wesierska-Gadek
    Division Institute of Cancer Research, Dept of Medicine I, Cell Cycle Regulation Group, Medical University of Vienna, Borschkegasse 8 a, A 1090 Vienna, Austria
    Expert Opin Investig Drugs 15:23-38. 2006
    ..Furthermore, there is also reason to believe that CDK2 inhibitors could be used for another purpose, to protect normal cells from the effects of chemotherapy...
  34. ncbi request reprint Phenol red in the culture medium strongly affects the susceptibility of human MCF-7 cells to roscovitine
    Jozefa Wesierska-Gadek
    Institute of Cancer Research, Department of Medicine I, Vienna Medical University, Vienna, Austria
    Cell Mol Biol Lett 12:280-93. 2007
    ..We observed that phenol red added to the culture medium strongly promoted the cell proliferation and cell cycle progression of human cells expressing the estrogen receptor, and affected their susceptibility to chemotherapy...
  35. ncbi request reprint Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Division Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8 a, A 1090 Vienna, Austria
    J Cell Biochem 100:865-74. 2007
    ..These results identify HIPK2 as a component of the ROSC-induced signaling pathway leading to the stabilization and activation of wt p53 protein...
  36. ncbi request reprint Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells
    Jozefa Wesierska-Gadek
    Department of Medicine I, Division Institute of Cancer Research, Cell Cycle Regulation Group, Vienna Medical University, Vienna, Austria
    J Cell Biochem 98:1367-79. 2006
    ..Therefore, the exposure of cancer patients to the estrogen mimics should be avoided at least during chemotherapy by CDK inhibitors...
  37. ncbi request reprint Prevention of farnesylation of c-Ha-Ras protein enhances synergistically the cytotoxic action of doxorubicin in cycling but not in quiescent cells
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, A 1090 Vienna, Austria
    J Cell Biochem 99:1664-76. 2006
    ..These results show two striking advantages of the combined treatment: the desired cytostatic effect on tumor cells at lower drug concentrations and clearly reduced adverse effects on quiescent cells...
  38. doi request reprint Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells
    Margarita Maurer
    Department of Medicine I, Div Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    Ann N Y Acad Sci 1171:250-6. 2009
    ..Exposure to ROSC of MCF-7 cells released from S-phase block increased the ratio of S-phase cells. These results indicate that the cell cycle status of cancer cells prior to the onset of therapy determines the outcome of treatment...
  39. ncbi request reprint Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells
    Jacek Wojciechowski
    Cell Cycle Regulation Group, Institute of Cancer Research, University of Vienna, Vienna, Austria
    Int J Cancer 106:486-95. 2003
    ..Our results show that disintegration of nucleoli is an early marker of ROSC-induced changes. Cell cycle arrest precedes the main wave of apoptosis...
  40. ncbi request reprint Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy
    Jozefa Wesierska-Gadek
    Institute of Cancer Research, Faculty of Medicine, University of Vienna, Vienna, Austria
    Int J Cancer 101:128-36. 2002
    ..This coincided with the increase of cellular p53 and preceded the nucleolar accumulation of p53 protein, indicating that repression of virally coded E6 protein by CP contributes to the restoration of p53 expression...
  41. ncbi request reprint Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells
    David Gritsch
    Cell Cycle Regulation Group, Div, Institute of Cancer Research, Dept of Medicine I, Medical University of Vienna, A 1090 Vienna, Austria
    J Exp Ther Oncol 9:37-45. 2011
    ..This was potentiated after co-treatment with estrogen. These results clearly indicate that the efficacy of treating ER-positive breast cancers by ROSC can be enhanced by combined application of antiestrogens...
  42. ncbi request reprint Combining an FPTase inhibitor with cisplatin facilitates induction of apoptosis in human A549 lung cancer cells
    Franziska Weber
    Cell Cycle Regulation Group, Div Institute of Cancer Research, Dept of Medicine I, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria
    J Exp Ther Oncol 9:53-65. 2011
    ..Our preliminary results indicate that functional p53 contributes to the outcome of the therapy in human A549 cells by certain anti-cancer drugs...
  43. ncbi request reprint Cellular and organismal ageing: Role of the p53 tumor suppressor protein in the induction of transient and terminal senescence
    Gerald Schmid
    Cell Cycle Regulation Group, Department of Medicine I, Division Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    J Cell Biochem 101:1355-69. 2007
    ..Therefore, modulating the expression of the truncated p53 isoform accordingly, might lead to increased health-span and elevated life-span...
  44. doi request reprint Monitoring of long-term effects of resveratrol on cell cycle progression of human HeLa cells after administration of a single dose
    Matthias P Kramer
    Department of Medicine I, Institute of Cancer Research, Medical University Vienna, Vienna, Austria
    Ann N Y Acad Sci 1171:257-63. 2009
    ..Four hours after medium change, more than 70% of cells moved into the G(2)/M phase. Moreover, resveratrol combined with ROSC enhanced the antiproliferative action of resveratrol...
  45. ncbi request reprint Non-apoptogenic killing of hela cervical carcinoma cells after short exposure to the alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Institute of Cancer Research, Faculty of Medicine, University of Vienna, Vienna, Austria
    J Cell Biochem 89:1222-34. 2003
    ..Since the alkylating agents generate DNA strand breaks, the recruitment of methods based on determination of DNA cleavage such as DNA ladder or TUNEL assay for evaluation of apoptosis is not adequate...
  46. ncbi request reprint Strong induction of p73 protein in vivo coincides with the onset of apoptosis in rat liver after treatment with the hepatocarcinogen N-nitrosomorpholine (NNM)
    Slavica Tudzarova-Trajkovska
    Cell Cycle Regulation Group, Institute of Cancer Research, University of Vienna, A 1090 Vienna, Austria
    J Cell Biochem 90:837-55. 2003
    ..Our data indicate that activated p73 protein may positively affect the induction and execution of apoptosis in response to genotoxic action of NNM...
  47. ncbi request reprint Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Institute of Cancer Research, University of Vienna, Borschkegasse 8a, A 1090 Vienna, Austria
    Pol J Pharmacol 55:895-902. 2003
    ..Reconstitution with caspase-3 sensitized MCF-7 cells to CP action. It implicates that ROSC inhibits more selectively and efficaciously the proliferation of human breast carcinoma cells...
  48. ncbi request reprint Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER
    Nora Zulehner
    Cell Cycle Regulation Group, Division, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria
    J Exp Ther Oncol 9:17-25. 2011
    ..The effect of TAM on ER-negative cancer cells indicates that TAM also crosstalks with other steroid hormone receptors...
  49. ncbi request reprint Induction of cell cycle arrest and apoptosis in human cervix carcinoma cells during therapy by cisplatin
    Daniela Schloffer
    Cell Cycle Regulation Group, Institute of Cancer Research, Faculty of Medicine, University of Vienna, Borschkegasse 8a, A 1090 Vienna, Austria
    Cancer Detect Prev 27:481-93. 2003
    ..Neither inhibition of cell division nor blocking of DNA replication preceded the onset of apoptosis. Our results show that after short treatment by CP, cell proliferation and apoptosis concomitantly occurred...
  50. doi request reprint Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?
    Stefanie Wandl
    Cell Cycle Regulation Group, Division Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Ann N Y Acad Sci 1171:242-9. 2009
    ..It remains to clarify whether the strong proapoptotic effect of OLO observed in HL-60 cells depends on their differentiation status...
  51. doi request reprint Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells
    Oxana Komina
    Cell Cycle Regulation Group, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8 a, A 1090 Vienna, Austria
    Biochem Pharmacol 76:1554-62. 2008
    ..Further analyses revealed that the combined treatment strongly activated caspase-3. These results clearly evidence that RES strongly potentiates ROSC-induced apoptosis...
  52. ncbi request reprint Triazoloacridone C-1305 abrogates the restriction checkpoint in cells lacking functional p53 and promotes their accumulation in the G2/M phase of the cell cycle
    Margarita Maurer
    Cell Cycle Regulation Group, Institute of Cancer Research, Dept of Medicine I, Medical University of Vienna, Vienna, Austria
    J Exp Ther Oncol 9:5-15. 2011
    ..These observations suggest that C-1305 abrogates the restriction checkpoint and promotes G1/S transition in cells lacking functional p53...
  53. ncbi request reprint Prevention of p53 degradation in human MCF-7 cells by proteasome inhibitors does not mimic the action of roscovitine
    Carmen Ranftler
    Division Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8 a, A 1090 Vienna, Austria
    Ann N Y Acad Sci 1090:234-44. 2006
    ..Our results indicate that prevention of p53 degradation by proteasome inhibitors does not mimic the action of ROSC...
  54. ncbi request reprint Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis
    Jozefa Wesierska-Gadek
    First Department of Internal Medicine, Institute of Cancer Research, Vienna Medical University, Vienna, Austria
    Hepatology 43:1135-44. 2006
    ..5%, P = .019). Anti-NPC antibodies remained stable or slightly increased over the period of observation. In condusion, anti-NPC identifies patients likely to experience an unfavorable clinical course and more rapid disease progression...
  55. ncbi request reprint Central and carboxy-terminal regions of human p53 protein are essential for interaction and complex formation with PARP-1
    Jozefa Wesierska-Gadek
    Institute of Cancer Research, University of Vienna, Vienna, Austria
    J Cell Biochem 89:220-32. 2003
    ....
  56. ncbi request reprint Advantage of a baculovirus expression system for protein-protein interaction studies. Involvement of posttranslational phosphorylation in the interaction between wt p53 protein and poly(ADP-ribose) polymerase-1
    Gerald Schmid
    Cell Cycle Regulation Group, Division Institute of Cancer Research, Department of Medicine I, Vienna Medical University, Vienna, Austria
    Acta Biochim Pol 52:713-9. 2005
    ....
  57. ncbi request reprint Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells
    Oxane Komina
    Cell Cycle Regulation Group, Division, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria
    J Exp Ther Oncol 9:27-35. 2011
    ..Inhibition of transcription of pro-survival genes such as BCL2 and MCL-1 as well as destabilization of survivin seems to improve its therapeutic efficacy...
  58. ncbi request reprint Phosphorylation regulates the interaction and complex formation between wt p53 protein and PARP-1
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Unit, Institute of Cancer Research, University of Vienna, Vienna, Austria
    J Cell Biochem 89:1260-84. 2003
    ..Our results unequivocally show that the presence of PARP-1 regulates the basal expression of wt p53 in unstressed cells...
  59. doi request reprint Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway
    Zsuzsanna Bago-Horvath
    Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
    Neuroendocrinology 96:228-37. 2012
    ..However, the impact of EGFR and mTOR expression and combined inhibition in neuroendocrine lung tumors other than small-cell lung cancer remains unclear...
  60. ncbi request reprint p53-mediated regulation of cell cycle progression: pronounced impact of cellular microenvironment
    Gerald Schmid
    Cell Cycle Regulation Group, Division Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria
    J Cell Physiol 219:459-69. 2009
    ....
  61. ncbi request reprint 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2
    Stephen Strasser
    Institute of Clinical Pathology, Medical University of Vienna, A 1090 Vienna, Austria
    Differentiation 74:488-98. 2006
    ..The acquisition of chemoresistance encompassed the affection of apoptosis- and cell-cycle regulation to, respectively, different extents. Thus, drug-induced cell cycle arrest and apoptosis induction are independent of each other...
  62. ncbi request reprint Anti-SLA seropositive autoimmune hepatitis sera recognize distinct subunits of glutathione S-transferase: high prevalence of the Ya autoantigen
    Jozefa Wesierska-Gadek
    Institute of Cancer Research, University of Vienna, Austria
    Cell Mol Biol (Noisy-le-grand) 48:301-7. 2002
    ..It would suggest that autoantibodies recognize distinct epitopes located within amino-terminus of individual GST variants...
  63. ncbi request reprint [New face of antiapoptotic proteins. II. Survivin]
    Jozefa Wesierska-Gadek
    Cell Cycle Regulation Group, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Postepy Biochem 53:239-53. 2007
    ..Moreover, insights into the development of new anti-cancer therapeutic strategies targeting survivin are overviewed...